氯喹在健康泰国受试者和间日疟原虫疟疾患者中的药代动力学。
The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria.
作者信息
Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-Ariya P, Karbwang J
机构信息
Clinical Pharmacology Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
出版信息
Br J Clin Pharmacol. 1994 Sep;38(3):278-81. doi: 10.1111/j.1365-2125.1994.tb04354.x.
Abstract
The pharmacokinetics of chloroquine (CQ) and desethylchloroquine (DECQ) were studied in seven male Thai patients with P. vivax malaria and seven healthy male Thais, after the standard oral dosage regimen of CQ (a total dose of 1500 mg given over 3 days). All patients showed a rapid initial response to the treatment with median (range) values of fever and parasite clearance times of 13.7 (2-47) and 58 (33-38) h, respectively. In the patients, the median range Cmax value was significantly higher (1547 (996-2446) vs 838 (656-1587) ng ml-1), and AUC(0,28d) was greater (281 (250-515) vs 122 (103-182) micrograms ml-1 h). In addition, the median (AUC(0,28d) of DECQ was significantly greater (170 (72-265) vs 77 (49-140) micrograms ml-1 h). The AUC(0,28d) ratio of DECQ to CQ in patients was significantly higher than that in healthy subjects (0.67 (0.43-0.90) vs 0.51 (0.29-0.61)).
摘要
对7名患间日疟原虫疟疾的泰国男性患者和7名健康泰国男性给予氯喹（CQ）标准口服给药方案（3天内共给予1500mg）后，研究了氯喹（CQ）和去乙基氯喹（DECQ）的药代动力学。所有患者对治疗均表现出快速的初始反应，发热和寄生虫清除时间的中位数（范围）分别为13.7（2 - 47）小时和58（33 - 38）小时。患者的Cmax值中位数范围显著更高（1547（996 - 2446）对838（656 - 1587）ng/ml），且AUC(0,28d)更大（281（250 - 515）对122（103 - 182）μg/ml·h）。此外，DECQ的AUC(0,28d)中位数显著更大（170（72 - 265）对77（49 - 140）μg/ml·h）。患者中DECQ与CQ的AUC(0,28d)比值显著高于健康受试者（0.67（0.43 - 0.90）对0.51（0.29 - 0.61））。
相似文献
1
The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria.氯喹在健康泰国受试者和间日疟原虫疟疾患者中的药代动力学。
Br J Clin Pharmacol. 1994 Sep;38(3):278-81. doi: 10.1111/j.1365-2125.1994.tb04354.x.
2
Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand.泰国间日疟原虫对氯喹标准疗法的临床反应及体外敏感性
Trans R Soc Trop Med Hyg. 1995 Jul-Aug;89(4):426-9. doi: 10.1016/0035-9203(95)90039-x.
3
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border.泰国-缅甸边境间日疟原虫感染患者三日氯喹治疗的群体药代动力学
Malar J. 2016 Feb 29;15:129. doi: 10.1186/s12936-016-1181-1.
4
Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children.单剂量氯喹在营养不良疟疾患儿中的药代动力学评估——与营养正常儿童的对比研究
Indian J Pharmacol. 2016 Sep-Oct;48(5):498-502. doi: 10.4103/0253-7613.190720.
5
Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria.间日疟孕妇与非孕妇中氯喹的药代动力学
Eur J Clin Pharmacol. 2008 Oct;64(10):987-92. doi: 10.1007/s00228-008-0500-z. Epub 2008 Jul 2.
6
Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.人群药代动力学和氯喹在间日疟原虫志愿者感染研究中的药效动力学。
Clin Pharmacol Ther. 2020 Nov;108(5):1055-1066. doi: 10.1002/cpt.1893. Epub 2020 Jul 2.
7
The extent of chloroquine underdosing in adult patients with malaria by Plasmodium vivax from an endemic area of the Brazilian Amazon basin.来自巴西亚马逊流域地方性流行区的间日疟原虫感染的成年疟疾患者中氯喹的低剂量使用程度。
Trop Med Int Health. 2020 Sep;25(9):1093-1097. doi: 10.1111/tmi.13459. Epub 2020 Jul 27.
8
9
Chloroquine-Primaquine Therapeutic Efficacy, Safety, and Plasma Levels in Patients with Uncomplicated Malaria in a Colombian Pacific Region.氯喹-伯氨喹治疗疗效、安全性及在哥伦比亚太平洋地区无并发症疟疾患者中的血浆水平。
Am J Trop Med Hyg. 2019 Jan;100(1):72-77. doi: 10.4269/ajtmh.18-0655.
10
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.埃塞俄比亚德布雷齐特的抗氯喹间日疟原虫疟疾
Malar J. 2008 Oct 29;7:220. doi: 10.1186/1475-2875-7-220.
引用本文的文献
1
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.与氯喹不同，盐酸甲氟喹可抑制生理相关细胞中的 SARS-CoV-2 感染。
Viruses. 2022 Feb 11;14(2):374. doi: 10.3390/v14020374.
2
Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients.氯喹与磷酸萘酚喹联合治疗间日疟患者的药代动力学无性别差异。
Rev Inst Med Trop Sao Paulo. 2020 Oct 30;62:e83. doi: 10.1590/S1678-9946202062083. eCollection 2020.
3
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.基于已建立的人体药代动力学得出的血浆和靶部位浓度，对抗 SARS-CoV-2 药物再利用机会进行优先排序。
Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14.
4
Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.人群药代动力学和氯喹在间日疟原虫志愿者感染研究中的药效动力学。
Clin Pharmacol Ther. 2020 Nov;108(5):1055-1066. doi: 10.1002/cpt.1893. Epub 2020 Jul 2.
5
High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS.使用液相色谱-串联质谱法（LC-MS/MS）定量测定人血样中氯喹及其代谢物的高灵敏度方法。
Bioanalysis. 2019 Mar;11(5):333-347. doi: 10.4155/bio-2018-0202. Epub 2019 Mar 15.
6
The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.奎宁和结构相关抗疟药物的致心律失常性心脏毒性：系统评价。
BMC Med. 2018 Nov 7;16(1):200. doi: 10.1186/s12916-018-1188-2.
7
Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children.单剂量氯喹在营养不良疟疾患儿中的药代动力学评估——与营养正常儿童的对比研究
Indian J Pharmacol. 2016 Sep-Oct;48(5):498-502. doi: 10.4103/0253-7613.190720.
8
Effect of Khat (Catha edulis) Use on the Bioavailability, Plasma Levels and Antimalarial Activity of Chloroquine.巧茶（Catha edulis）的使用对氯喹生物利用度、血浆水平及抗疟活性的影响。
Sultan Qaboos Univ Med J. 2016 May;16(2):e182-8. doi: 10.18295/squmj.2016.16.02.008. Epub 2016 May 15.
9
Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity.氯喹可用于治疗丝状病毒感染以及其他因病毒感染性需要酸性pH值而出现或曾经出现过的病毒感染。
Cell Biochem Funct. 2016 Jun;34(4):191-6. doi: 10.1002/cbf.3182. Epub 2016 Mar 21.
10
Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.马来酸蒿乙醚胺与磷酸哌喹固定剂量复方制剂和氯喹治疗急性非复杂性间日疟安全性及有效性比较：一项III期、多中心、开放标签研究
Malar J. 2016 Jan 27;15:42. doi: 10.1186/s12936-016-1084-1.
本文引用的文献
1
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.采用液相色谱法测定血浆、红细胞和尿液中的氯喹及其去乙基代谢物。
J Chromatogr. 1982 Apr 16;229(1):241-7. doi: 10.1016/s0378-4347(00)86059-4.
2
On the question of dose-dependent chloroquine elimination of a single oral dose.
Clin Pharmacol Ther. 1983 Sep;34(3):383-5. doi: 10.1038/clpt.1983.183.
3
Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma.氯喹及其代谢产物去乙基氯喹在人体血细胞中的分布及其对血清和血浆中这些化合物定量测定的意义。
J Chromatogr. 1983 Jan 14;272(1):137-48. doi: 10.1016/s0378-4347(00)86110-1.
4
Pharmacokinetics of chloroquine in Thais: plasma and red-cell concentrations following an intravenous infusion to healthy subjects and patients with Plasmodium vivax malaria.氯喹在泰国人中的药代动力学：对健康受试者和间日疟原虫疟疾患者静脉输注后的血浆和红细胞浓度
Br J Clin Pharmacol. 1988 Apr;25(4):477-85. doi: 10.1111/j.1365-2125.1988.tb03332.x.
5
A mixed infection of vivax and falciparum malaria apparently resistant to 4-aminoquinoline: a case report.间日疟和恶性疟的混合感染，对4-氨基喹啉明显耐药：病例报告
Trans R Soc Trop Med Hyg. 1989 Sep-Oct;83(5):607-8. doi: 10.1016/0035-9203(89)90370-2.
6
Development of in vitro microtest for the assessment of Plasmodium vivax sensitivity to chloroquine.
Southeast Asian J Trop Med Public Health. 1989 Mar;20(1):41-7.
7
Chloroquine-resistant Plasmodium vivax.氯喹耐药间日疟原虫
Lancet. 1989 Dec 9;2(8676):1395. doi: 10.1016/s0140-6736(89)92002-3.
8
Plasmodium vivax resistance to chloroquine?间日疟原虫对氯喹耐药？
Lancet. 1989 Nov 18;2(8673):1183-4. doi: 10.1016/s0140-6736(89)91792-3.
9
Chloroquine-resistant Plasmodium vivax from Indonesia.来自印度尼西亚的抗氯喹间日疟原虫。
N Engl J Med. 1991 Mar 28;324(13):927. doi: 10.1056/NEJM199103283241317.
10
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia.印度尼西亚伊里安查亚间日疟原虫对氯喹的抗药性
Am J Trop Med Hyg. 1991 May;44(5):547-52. doi: 10.4269/ajtmh.1991.44.547.
Zotero 插件